No Detail Found!

Rescue therapy with Sofosbuvir /Velpatasvir/ Voxilaprevir in a patient infected with Hepatitis C virus multidrug resistant variant-a much needed option for DAA-treatment failures in Pakistan? A case-report

Author(s)
Ambreen Arif Department of Hepatology, Private Clinic, Karachi, Pakistan
Huma Qureshi Department of Gastroenterology, Private Clinic, Karachi, Pakistan
Abstract
Primary non-response to the currently available direct acting anti-viral (DAAs) in chronic hepatitis C virus (HCV) is rare and expected in approximately only 3-4% of the patients. Among the plausible explanations, HCV resistant variant may be one of the causes among the several other viral and host factors implicated in cases who do not achieve cure. Ever since the approval of licensed DAAs in 2014, focus has been mainly on high cure rates. Hence, significantly less attention has been given to the few difficult to treat cases. We present, herein, the case of a 50-year old male who had previously failed to respond to the currently available first and second-line DAA treatment and was then approved for a special treatment access programme. According to our knowledge this is the first case-report from Pakistan in favour of the physician's directive for special treatment access for HCV DAA-experienced patients.
Publication Details
Page(s) 1875-1877
Published Journal: Journal of Pakistan Medical Association, Volume: 74, Issue: 10, Year: 2024

Request the full text from PASTIC

Keywords
Hepatitis C virus, Pakistan, Standard of care, Direct acting anti-virals
0

Citations

0

Downloads

75

Views